Vanta Bioscience Ltd (VANTABIO)

Loading page…

Vanta Bioscience Ltd (VANTABIO) · mywealthgrid

About

Vanta Bioscience Ltd operates in Healthcare Research, Analytics & Technology within the Healthcare sector.

Face value: ₹10

Market cap

₹15 Cr

P/E

138.7×

P/B

—

Dividend yield

ROE

—

ROCE

—

Debt / equity

—

OPM

56.6%

EPS (TTM)

₹0.2

Book value

—

52-week high

—

52-week low

—

1,240 historical price candles were omitted because the exchange source has not been verified.

₹21.5-0.3%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 56.6%
+High promoter holding of 72.8% with no pledge

Cons

−Low return on equity of -27.5% (3-yr avg)
−Profit declined 24.6% a year over the last 5 years
−Revenue shrank over the last 5 years (-28.9% a year)
−Weak interest coverage of 1×
−Expensive at 138.7× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

17/100

Business quality: 50
Growth: 0

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Syngene International LimitedSYNGENESYNGENE	₹14,586 Cr	₹14,595 Cr	₹3,600 Cr	₹803 Cr	24.6%	₹221 Cr	8.5%	9.8%	6.6%	-32
Indegene LimitedINDGNINDGN	₹14,303 Cr	₹14,303 Cr	₹3,813 Cr	₹638 Cr	17.6%	₹401 Cr	11.4%	17.9%	13.9%	79
Suven Life Sciences LimitedSUVENSUVEN	₹8,139 Cr	₹8,139 Cr	₹9 Cr	₹-366 Cr	—	₹-352 Cr	—	-78.4%	-78.8%	72
Vimta Labs LimitedVIMTALABSVIMTALABS	₹2,612 Cr	₹2,631 Cr	₹336 Cr	₹112 Cr	27.3%	₹61 Cr	12.9%	17.4%	13.6%	179
Bilcare LimitedBIBI	₹227 Cr	₹896 Cr	₹788 Cr	₹45 Cr	5.7%	₹-29 Cr	-7.1%	1.5%	-6%	78
Take Solutions LimitedTAKETAKE	₹187 Cr	₹187 Cr	₹85 Cr	₹-2 Cr	-3.5%	₹13 Cr	20%	18.5%	42.1%	-7
Jeevan Scientific Technology LtdJSTLJSTL	₹169 Cr	₹186 Cr	₹62 Cr	₹10 Cr	16%	₹0 Cr	1.7%	5.4%	1.7%	-109
Novelix Pharmaceuticals LtdNOVELIXNOVELIX	₹167 Cr	₹167 Cr	₹9 Cr	₹-3 Cr	-29.9%	₹-2 Cr	-23.6%	-28.1%	-28.5%	57
Globalspace Technologies LtdGSTLGSTL	₹103 Cr	—	₹25 Cr	₹11 Cr	5.9%	₹7 Cr	-1.4%	—	—	—
Adeshwar Meditex LtdADESHWARADESHWAR	₹23 Cr	—	₹56 Cr	₹3 Cr	4.9%	₹1 Cr	2.3%	—	—	—
Vanta Bioscience LtdVANTABIOVANTABIO	₹15 Cr	—	₹2 Cr	₹1 Cr	56.6%	₹0 Cr	6%	—	—	—

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10	10	6	10	2	2
COGS	1	1	1	1	1	-1
Gross profit	9	9	5	9	1	—
	5	6	8	8	5	2
	4	3	-2	1	-4	1
OPM %	39.3%	35.9%	-38.1%	13.5%	-216.8%	56.6%
Depreciation	1	1	3	5	4	0
Interest	2	2	6	6	4	1
	0	0	1	0	0	0
Profit before tax	1	0	-10	-9	-13	0
Tax	0	0	0	-0	1	-0
Tax %	23.7%	60.9%	1.8%	-2.5%	5.2%	-900%
	0	0	-6	-2	-5	0
PAT margin %	4.5%	0.9%	-103.2%	-23.9%	-243.4%	6%
EPS (₹)	0.7	0.1	-10.3	-3.7	-7.6	0.2
EPS adjusted (₹)	0.7	0.1	-10.3	-3.7	-7.6	—
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	6	6	6	6	6	—
Reserves	18	18	11	9	4	—
	32	45	57	61	70	—
	14	13	10	9	5	66
Total equity & liabilities	70	81	85	85	86	66
	29	36	57	54	24	10
CWIP	19	—	—	—	—	—
Investments	0	0	0	0	0	3
	21	45	27	31	62	53
Total assets	70	81	85	85	86	66

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	7	5	-1	3	-2	-5
	-22	-17	-6	-3	-7	-7
	18	9	6	1	9	12
Net cash flow	2	-2	-0	0	0	-0
Free cash flow	6	5	-29	-1	-9	-5
CFO / Operating profit %	176.5%	151.7%	—	204.6%	—	-506.8%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	91.8%	92.8%	85%	92.6%	31.6%	—
EBITDA margin %	39.3%	35.9%	-38.1%	13.5%	-216.8%	56.6%
EBIT margin %	26.9%	22.3%	-80.6%	-32.8%	-442.3%	35.2%
PAT margin %	4.5%	0.9%	-103.2%	-23.9%	-243.4%	6%
Working capital
Receivable days	73	43	114	118	466	—
Inventory days	4,344	3,775	2,780	3,812	1,773	3,479
Payable days	1,714	1,283	1,639	2,824	1,346	—
NWC days	2,704	2,535	1,256	1,106	893	—
Leverage
Current ratio	1.34	1.02	0.86	0.75	0.58	1.2
Debt to EBITDA	8.1	12.89	—	46.53	—	—
Debt to equity	1.34	1.87	3.26	4.01	6.73	—
Interest coverage	1.3	1.1	-0.7	-0.5	-2.1	1
Asset turnover	0.14	0.12	0.07	0.11	0.02	0.03
Return ratios
Return on assets %	0.6%	0.1%	-7.6%	-2.7%	-5.6%	0.2%
Return on capital employed %	5%	4.2%	-6.5%	-4.8%	-14%	1.4%
Return on equity %	1.9%	0.4%	-37%	-15.3%	-45.8%	—

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
	69.36%	69.36%	72.81%	72.81%	72.81%
FII	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%
	30.64%	30.64%	27.19%	27.19%	27.19%
No. of shareholders	424	408	408	419	426

Promoter holding up 3.45 percentage points since Sep 2024.

Dopesh Raja MulakalaManaging Director
Dr. Padmanabhuni Venkata AppajiDirector
Mr. Dokka Venkata Sathya MuraliChief Financial Officer
Dr. Kathyayani GonuguntlaDirector
Dr. Yogeswara Rao DandaDirector
Ms. Pooja KothariCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Vanta Bioscience Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

4 announcementsExport CSV

30 Sept 2026, 7:11 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	91.8%	92.8%	85%	92.6%	31.6%	—
EBITDA margin %	39.3%	35.9%	-38.1%	13.5%	-216.8%	56.6%
EBIT margin %	26.9%	22.3%	-80.6%	-32.8%	-442.3%	35.2%
PAT margin %	4.5%	0.9%	-103.2%	-23.9%	-243.4%	6%
Working capital
Receivable days	73	43	114	118	466	—
Inventory days	4,344	3,775	2,780	3,812	1,773	3,479
Payable days	1,714	1,283	1,639	2,824	1,346	—
NWC days	2,704	2,535	1,256	1,106	893	—
Leverage
Current ratio	1.34	1.02	0.86	0.75	0.58	1.2
Debt to EBITDA	8.1	12.89	—	46.53	—	—
Debt to equity	1.34	1.87	3.26	4.01	6.73	—
Interest coverage	1.3	1.1	-0.7	-0.5	-2.1	1
Asset turnover	0.14	0.12	0.07	0.11	0.02	0.03
Return ratios
Return on assets %	0.6%	0.1%	-7.6%	-2.7%	-5.6%	0.2%
Return on capital employed %	5%	4.2%	-6.5%	-4.8%	-14%	1.4%
Return on equity %	1.9%	0.4%	-37%	-15.3%	-45.8%	—

Date	Category	Subject	Filing
30 Sept 2026, 7:11 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 7:08 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
29 Sept 2026, 3:21 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
5 Sept 2026, 4:57 pm	Others Outcome without intimation	Board Meeting Outcome for Outcome Of Board Meeting Held On 05.09.2026 - 10Th Annual General Meeting ('AGM') To Be Held On 30.09.2026	PDF

Vanta Bioscience Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

No events on record

Announcements

Not in the F&O segment

No fund holdings on record

No events on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Vanta Bioscience Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

No events on record

Announcements

Ratio timeline

Quarterly record

Board and management

Not in the F&O segment

No fund holdings on record

No events on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity